Q-omics provides the consensus-scored ATP6V1E1P2 profile across patient tissues and cancer cell-line models. ATP6V1E1P2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ATP6V1E1P2 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, ATP6V1E1P2 RNA expression shows 9,853 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, COAD, and GBM as cancer lineages where ATP6V1E1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP6V1E1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP6V1E1P2 survival associations across molecular data types. ATP6V1E1P2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP6V1E1P2 RNA expression–survival associations across cancer types. High ATP6V1E1P2 expression shows unfavorable associations in KICH, BLCA, CHOL, LIHC, MESO and DLBC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ATP6V1E1P2 RNA expression.
This table summarizes ATP6V1E1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ATP6V1E1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP6V1E1P2 shows lower tumor expression in THCA and higher tumor expression in COAD. The COAD box plot shows higher ATP6V1E1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.078, t-test p = .023).
This table shows molecular features associated with ATP6V1E1P2 in patient tissues and cancer cell lines. In patient samples, ATP6V1E1P2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
